Molecular Partners AG
NASDAQ:MOLN

Watchlist Manager
Molecular Partners AG Logo
Molecular Partners AG
NASDAQ:MOLN
Watchlist
Price: 4.3001 USD -2.93% Market Closed
Market Cap: 142.7m USD
Section:
 

Relative Value

The Relative Value of one MOLN stock under the Base Case scenario is 7.6121 USD. Compared to the current market price of 4.3001 USD, Molecular Partners AG is Undervalued by 44%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

MOLN Relative Value
Base Case
7.6121 USD
Undervaluation 44%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

N/A
P/S
P/S
Price to Sales
N/A
vs History
vs Industry
35
Median 3Y
12.8
Median 5Y
17.8
Industry
7.9
Forward
186.2
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
13
Median 3Y
-1.8
Median 5Y
-2
Industry
23.7
Forward
-2.2
More Details
Negative
P/OCF
P/OCF
Price to OCF
N/A
vs History
vs Industry
14
Median 3Y
-2
Median 5Y
-2.2
Industry
22
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
10
Median 3Y
-2
Median 5Y
-2.1
Industry
24.3
More Details
1.3
P/B
P/B
Price to Book Value
1.3
vs History
30
vs Industry
61
Median 3Y
0.9
Median 5Y
1
Industry
3.3
More Details
N/A
EV/S
EV/S
Enterprise Value to Sales
N/A
vs History
vs Industry
70
Median 3Y
-2.7
Median 5Y
-0.2
Industry
8.2
Forward
32.9
More Details
N/A
EV/GP
EV/GP
Enterprise Value to Gross Profit
N/A
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
10.2
More Details
Negative
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
N/A
vs History
vs Industry
30
Median 3Y
-0
Median 5Y
-0.4
Industry
6.1
Forward
-0.4
More Details
Negative
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
N/A
vs History
vs Industry
28
Median 3Y
-0
Median 5Y
-0.4
Industry
6.5
Forward
-0.4
More Details
Negative
EV/OCF
EV/OCF
Enterprise Value to OCF
N/A
vs History
vs Industry
31
Median 3Y
-0
Median 5Y
-0.5
Industry
7.9
More Details
Negative
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
N/A
vs History
vs Industry
27
Median 3Y
-0
Median 5Y
-0.5
Industry
6.3
More Details
4.1
EV/IC
EV/IC
Enterprise Value to IC
4.1
vs History
33
vs Industry
41
Median 3Y
-3.9
Median 5Y
-0.5
Industry
5.7
More Details

Multiples Across Competitors

MOLN Competitors Multiples
Molecular Partners AG Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
CH
Molecular Partners AG
NASDAQ:MOLN
126.6m USD 0 -2.1 -0.4 -0.4
FR
Pharnext SCA
OTC:PNEXF
6T USD 33 766 261.7 -160 486 -194 881.2 -192 657.4
US
Abbvie Inc
NYSE:ABBV
406B USD 6.8 172.9 16.7 23.7
US
Amgen Inc
NASDAQ:AMGN
176.8B USD 4.9 25.2 18.2 18.2
US
Gilead Sciences Inc
NASDAQ:GILD
153B USD 5.3 18.9 12.7 12.7
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
115.2B USD 9.8 31.4 23 24
US
Epizyme Inc
F:EPE
94.1B EUR 2 086.4 -532.4 -579.7 -564.3
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
81.5B USD 5.7 17.8 17 19.3
AU
CSL Ltd
ASX:CSL
83.3B AUD 3.6 18.6 12.6 15.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
52.4B USD 16.3 1 201.7 162 196.5
NL
argenx SE
XBRU:ARGX
43.6B EUR 14.2 33.4 57.6 59.2
P/S Multiple
Revenue Growth P/S to Growth
CH
Molecular Partners AG
NASDAQ:MOLN
Average P/S: 3 376 841.5
Not Available
95%
N/A
FR
Pharnext SCA
OTC:PNEXF
33 766 261.7
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6.8
9%
0.8
US
Amgen Inc
NASDAQ:AMGN
4.9
5%
1
US
Gilead Sciences Inc
NASDAQ:GILD
5.3
4%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
9.8
10%
1
US
E
Epizyme Inc
F:EPE
2 086.4
N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.7
6%
1
AU
CSL Ltd
ASX:CSL
3.6
5%
0.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
16.3
46%
0.4
NL
argenx SE
XBRU:ARGX
14.2
49%
0.3
P/E Multiple
Earnings Growth PEG
CH
Molecular Partners AG
NASDAQ:MOLN
Average P/E: 190
Negative Multiple: -2.1 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -160 486 N/A N/A
US
Abbvie Inc
NYSE:ABBV
172.9
89%
1.9
US
Amgen Inc
NASDAQ:AMGN
25.2
45%
0.6
US
Gilead Sciences Inc
NASDAQ:GILD
18.9
190%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
31.4
N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -532.4 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.8
10%
1.8
AU
CSL Ltd
ASX:CSL
18.6
11%
1.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
1 201.7
N/A N/A
NL
argenx SE
XBRU:ARGX
33.4
40%
0.8
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
CH
Molecular Partners AG
NASDAQ:MOLN
Average EV/EBITDA: 40
Negative Multiple: -0.4 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -194 881.2 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16.7
14%
1.2
US
Amgen Inc
NASDAQ:AMGN
18.2
11%
1.7
US
Gilead Sciences Inc
NASDAQ:GILD
12.7
7%
1.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
23
16%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -579.7 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17
11%
1.5
AU
CSL Ltd
ASX:CSL
12.6
8%
1.6
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
162
N/A N/A
NL
argenx SE
XBRU:ARGX
57.6
810%
0.1
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
CH
Molecular Partners AG
NASDAQ:MOLN
Average EV/EBIT: 46.2
Negative Multiple: -0.4 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -192 657.4 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.7
30%
0.8
US
Amgen Inc
NASDAQ:AMGN
18.2
20%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
12.7
12%
1.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24
16%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -564.3 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
19.3
13%
1.5
AU
CSL Ltd
ASX:CSL
15.7
11%
1.4
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
196.5
N/A N/A
NL
argenx SE
XBRU:ARGX
59.2
N/A N/A

See Also

Summary
MOLN intrinsic value, competitors valuation, and company profile.
DCF Valuation
MOLN stock valuation using Discount Cash Flow valuation method.
Relative Valuation
MOLN stock valuation using valuation multiples.
Wall Street Estimates
MOLN price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
MOLN stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 306,100+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.